XNAS
APGE
Market cap2.43bUSD
Jul 25, Last price
40.82USD
1D
-1.97%
1Q
10.77%
IPO
96.25%
Name
Apogee Therapeutics Inc
Chart & Performance
Profile
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
---|---|---|---|
2024‑12 | 2023‑12 | 2022‑12 | |
Income | |||
Revenues | |||
Cost of revenue | 216,870 | 93,003 | 30,727 |
Unusual Expense (Income) | |||
NOPBT | (216,870) | (93,003) | (30,727) |
NOPBT Margin | |||
Operating Taxes | (18) | (34) | |
Tax Rate | |||
NOPAT | (216,852) | (93,003) | (30,693) |
Net income | (83,985) 111.10% | (39,785) | |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 493,483 | 315,391 | 168,317 |
BB yield | -19.74% | -0.05% | |
Debt | |||
Debt current | 3,234 | 2,202 | |
Long-term debt | 20,428 | 2,967 | |
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | (496,991) | (390,290) | (151,890) |
Cash flow | |||
Cash from operating activities | (171,174) | (74,761) | (16,427) |
CAPEX | (1,152) | (167) | |
Cash from investing activities | (300,462) | (273,910) | |
Cash from financing activities | 495,109 | 315,391 | 184 |
FCF | (227,582) | (95,597) | |
Balance | |||
Cash | 520,653 | 395,459 | 151,890 |
Long term investments | |||
Excess cash | 520,653 | 395,459 | 151,890 |
Stockholders' equity | (305,000) | (123,441) | (79,570) |
Invested Capital | 1,033,625 | 506,489 | 79,570 |
ROIC | |||
ROCE | |||
EV | |||
Common stock shares outstanding | 55,194 | 25,005,774 | 50,674 |
Price | 45.30 62.13% | 27.94 | |
Market cap | 2,500,287 -99.64% | 698,661,326 | |
EV | 2,003,296 | 698,271,036 | |
EBITDA | (216,681) | (93,003) | (30,727) |
EV/EBITDA | |||
Interest | 9,150 | ||
Interest/NOPBT |